Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Eli Lilly wants the black market for one of its most promising obesity drugs shut down, and it’s turning to the courts to make that happen. The company announced six new lawsuits this week. Each one targets a business accused…
GLP-1 drugs aren’t just for diabetes anymore. These medications now treat weight loss and obstructive sleep apnea too, and researchers keep finding new uses for them. Here’s how they work. GLP-1 drugs copy a natural hormone called glucagon-like peptide-1. That…
The rivalry between the two biggest names in weight loss medicine just moved into a federal courtroom. Novo Nordisk filed a lawsuit against Eli Lilly on July 21, 2026. The company filed it in the U.S. District Court for the…
Eli Lilly had a busy few weeks. The company closed its first quarter of 2026 with strong numbers. But the real story goes beyond earnings. Two separate developments deserve attention, and they touch very different corners of medicine. First, there’s…
Eli Lilly just posted numbers that turned heads across the pharmaceutical industry. The company brought in $19.8 billion in revenue for the first quarter of fiscal 2026. That’s a 56 percent jump from last year. Two drugs drove much of…
A new forecast from pharmaceutical intelligence firm Evaluate suggests Eli Lilly’s tirzepatide franchise is on track to make commercial history. The company’s World Preview report projects that Mounjaro and Zepbound could together generate more than $70 billion in annual sales…
Novo Nordisk’s new weight-loss pill is quickly moving ahead of Eli Lilly’s competitor, and experts say the reason is simple: doctors trust what they already know. Even though Eli Lilly launched its own pill, Foundayo, soon after Novo Nordisk introduced…
Eli Lilly entered June 2026 with something most pharmaceutical companies spend years chasing: clinical data so compelling that competitors can barely keep pace. At the American Diabetes Association’s annual Scientific Sessions, the company unveiled extended trial results for retatrutide. Clinicians,…
For years, the biggest hurdle with GLP-1 medications wasn’t effectiveness. It was the needle. So Eli Lilly’s orforglipron may have just changed that entirely. The FDA approved orforglipron on April 1, 2026, for chronic weight management. Specifically, it targets adults…
Eli Lilly may be getting closer to putting a weight loss pill on pharmacy shelves. The company recently announced strong results from a large Phase 3 trial of orforglipron. It’s an experimental daily pill designed to work like injectable GLP-1…